Sun Pharmaceutical Industries (SUNPHARMA) Investor presentation summary

Business overview and global presence

• Operates in over 100 countries with a diversified portfolio including specialty, branded generics, generics, and APIs.

• Largest pharmaceutical company in India and 12th largest in US generics market.

• 41 manufacturing facilities globally, with approvals from major regulators including USFDA.

• Over 43,000 employees worldwide, with a strong focus on quality compliance.

• Expanding presence in ex-US developed markets and emerging markets.

Financial performance and growth

• FY24 sales reached Rs 478 Bn, with a 15-year sales CAGR of 18%.

• EBITDA margin for FY24 at 26.9%, with gross margin at 77.7%.

• Adjusted net profit CAGR of 12% from FY09 to FY24.

• Market capitalization at US $47 Bn as of February 2025.

• Strong free cash flow and consistent improvement in ROCE and ROE.

Revenue composition and business segments

• US formulations contributed 32%, India 31%, Emerging Markets 18%, Rest of World 14%, and API & Others 5% to FY24 sales.

• Specialty products accounted for over 18% of total sales in FY24.

• India business holds 8.2% market share, leading in 12 therapeutic areas.

• US business is the 12th largest generics player, with a robust pipeline and recent acquisitions.

• Emerging Markets and Rest of World segments have strong local manufacturing and sales presence.